Daunorubicin‐prednisone remission induction with hydroxyurea maintenance in acute non‐lymphocytic leukemia

Clara D. Bloomfield, Richard D. Brunning, Athanasios Theologides, B. J. Kennedy

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Forty‐five adults with acute non‐lymphocytic leukemia were treated with daunorubicin and prednisone. Twelve complete and four partial remissions were obtained. On hydroxyurea maintenance, remissions lasted a median of 6 months. The most important factors influencing remission induction were age and sex, and pretreatment absolute blast count. All 14 men over the age of 40 failed to respond while 50% of all other patients responded. Patients with low absolute blast counts were more likely to respond. A review of the literature reveals a similar overall complete remission rate of 26% using daunorubicin alone; thus adding prednisone to daunorubicin does not appear to increase the percentage of complete remissions. Hydroxyurea resulted in longer remissions than have been previously reported following daunorubicin induction; it merits further investigation as a maintenance agent.

Original languageEnglish (US)
Pages (from-to)931-938
Number of pages8
JournalCancer
Volume31
Issue number4
DOIs
StatePublished - Apr 1973

Fingerprint Dive into the research topics of 'Daunorubicin‐prednisone remission induction with hydroxyurea maintenance in acute non‐lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this